Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder Perspective

Tejen Shah,1 Stacy Brethauer,1 Walter A Danker III,2 Ishita Doshi,2 Matthew O’Hara,3 Abigail Silber,3 William K Vasileff4 1Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA; 2Ethicon, Inc., Raritan, NJ, USA; 3Trinity Life Sciences, Waltham, MA, USA; 4Departmen...

Full description

Saved in:
Bibliographic Details
Main Authors: Shah T, Brethauer S, Danker III WA, Doshi I, O'Hara M, Silber A, Vasileff WK
Format: Article
Language:English
Published: Dove Medical Press 2025-01-01
Series:Medical Devices: Evidence and Research
Subjects:
Online Access:https://www.dovepress.com/implementation-of-a-cost-and-variation-reduction-program-for-hemostasi-peer-reviewed-fulltext-article-MDER
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832590400395673600
author Shah T
Brethauer S
Danker III WA
Doshi I
O'Hara M
Silber A
Vasileff WK
author_facet Shah T
Brethauer S
Danker III WA
Doshi I
O'Hara M
Silber A
Vasileff WK
author_sort Shah T
collection DOAJ
description Tejen Shah,1 Stacy Brethauer,1 Walter A Danker III,2 Ishita Doshi,2 Matthew O’Hara,3 Abigail Silber,3 William K Vasileff4 1Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA; 2Ethicon, Inc., Raritan, NJ, USA; 3Trinity Life Sciences, Waltham, MA, USA; 4Department of Orthopaedics, Sports Medicine Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USACorrespondence: Stacy Brethauer, Email Stacy.Brethauer@osumc.eduGoal: Cost-saving initiatives targeting surgical supplies management have become increasingly common to address rising healthcare costs. However, few studies provide details on hospital stakeholder experiences or learnings from implementing such initiatives. Thus, we sought to evaluate hospital stakeholder satisfaction with conversion to a sole supplier for hemostasis products, in addition to economic and clinical impacts, to help develop best practices for implementation.Methods: This cross-sectional study assessed satisfaction with converting to a sole supplier for hemostasis products at a large US academic medical center using qualitative interviews and quantitative surveys with clinical and non-clinical stakeholders, on the decision-making process, conversion, and vendor-supported hemostasis optimization program (HOP) post-implementation (February 2022–May 2022). Perioperative hemorrhage events, adjunctive hemostat utilization, and total annual hospital expenditure on hemostatic products were also evaluated pre- and post-conversion (2020– 2022) to identify impacts on clinical and economic outcomes.Findings: Ten hospital stakeholders completed qualitative interviews (n = 7 surgeons, n = 2 surgical technicians, n = 1 administrator) and 22 completed quantitative surveys (n = 6 surgeons, n = 5 surgical technicians, n = 11 nurses). Survey respondents noted overall satisfaction with conversion, including the level of input they provided in the decision-making process (75% were somewhat to extremely satisfied), availability of hemostatic agents during the conversion process (87%), and the vendor-supported HOP (100%). The outcomes analyses revealed a nearly 25% decrease in supply expenditure without changes to the number of postoperative hemorrhage events following implementation.Practical Applications: Converting to a sole vendor for hemostasis products was achieved with high satisfaction among hospital stakeholders and cost savings to the institution without impacting the quality of patient care. This study provides a roadmap of best practices for other institutions interested in implementing similar initiatives and presents an example of a successful transition to a sole vendor for hemostasis products driven by effective supplier, institution, and hospital stakeholder coordination.Keywords: hemostatic agent, cost savings, variation reduction, surgical care, hospital inventory
format Article
id doaj-art-7628a149cec4478e8b9cd61c848b1a8e
institution Kabale University
issn 1179-1470
language English
publishDate 2025-01-01
publisher Dove Medical Press
record_format Article
series Medical Devices: Evidence and Research
spelling doaj-art-7628a149cec4478e8b9cd61c848b1a8e2025-01-23T18:50:33ZengDove Medical PressMedical Devices: Evidence and Research1179-14702025-01-01Volume 18637399548Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder PerspectiveShah TBrethauer SDanker III WADoshi IO'Hara MSilber AVasileff WKTejen Shah,1 Stacy Brethauer,1 Walter A Danker III,2 Ishita Doshi,2 Matthew O’Hara,3 Abigail Silber,3 William K Vasileff4 1Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA; 2Ethicon, Inc., Raritan, NJ, USA; 3Trinity Life Sciences, Waltham, MA, USA; 4Department of Orthopaedics, Sports Medicine Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USACorrespondence: Stacy Brethauer, Email Stacy.Brethauer@osumc.eduGoal: Cost-saving initiatives targeting surgical supplies management have become increasingly common to address rising healthcare costs. However, few studies provide details on hospital stakeholder experiences or learnings from implementing such initiatives. Thus, we sought to evaluate hospital stakeholder satisfaction with conversion to a sole supplier for hemostasis products, in addition to economic and clinical impacts, to help develop best practices for implementation.Methods: This cross-sectional study assessed satisfaction with converting to a sole supplier for hemostasis products at a large US academic medical center using qualitative interviews and quantitative surveys with clinical and non-clinical stakeholders, on the decision-making process, conversion, and vendor-supported hemostasis optimization program (HOP) post-implementation (February 2022–May 2022). Perioperative hemorrhage events, adjunctive hemostat utilization, and total annual hospital expenditure on hemostatic products were also evaluated pre- and post-conversion (2020– 2022) to identify impacts on clinical and economic outcomes.Findings: Ten hospital stakeholders completed qualitative interviews (n = 7 surgeons, n = 2 surgical technicians, n = 1 administrator) and 22 completed quantitative surveys (n = 6 surgeons, n = 5 surgical technicians, n = 11 nurses). Survey respondents noted overall satisfaction with conversion, including the level of input they provided in the decision-making process (75% were somewhat to extremely satisfied), availability of hemostatic agents during the conversion process (87%), and the vendor-supported HOP (100%). The outcomes analyses revealed a nearly 25% decrease in supply expenditure without changes to the number of postoperative hemorrhage events following implementation.Practical Applications: Converting to a sole vendor for hemostasis products was achieved with high satisfaction among hospital stakeholders and cost savings to the institution without impacting the quality of patient care. This study provides a roadmap of best practices for other institutions interested in implementing similar initiatives and presents an example of a successful transition to a sole vendor for hemostasis products driven by effective supplier, institution, and hospital stakeholder coordination.Keywords: hemostatic agent, cost savings, variation reduction, surgical care, hospital inventoryhttps://www.dovepress.com/implementation-of-a-cost-and-variation-reduction-program-for-hemostasi-peer-reviewed-fulltext-article-MDERhemostatic agentcost savingsvariation reductionsurgical carehospital inventory
spellingShingle Shah T
Brethauer S
Danker III WA
Doshi I
O'Hara M
Silber A
Vasileff WK
Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder Perspective
Medical Devices: Evidence and Research
hemostatic agent
cost savings
variation reduction
surgical care
hospital inventory
title Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder Perspective
title_full Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder Perspective
title_fullStr Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder Perspective
title_full_unstemmed Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder Perspective
title_short Implementation of a Cost and Variation Reduction Program for Hemostasis Products at a Large Academic Medical Center: A Multi-Stakeholder Perspective
title_sort implementation of a cost and variation reduction program for hemostasis products at a large academic medical center a multi stakeholder perspective
topic hemostatic agent
cost savings
variation reduction
surgical care
hospital inventory
url https://www.dovepress.com/implementation-of-a-cost-and-variation-reduction-program-for-hemostasi-peer-reviewed-fulltext-article-MDER
work_keys_str_mv AT shaht implementationofacostandvariationreductionprogramforhemostasisproductsatalargeacademicmedicalcenteramultistakeholderperspective
AT brethauers implementationofacostandvariationreductionprogramforhemostasisproductsatalargeacademicmedicalcenteramultistakeholderperspective
AT dankeriiiwa implementationofacostandvariationreductionprogramforhemostasisproductsatalargeacademicmedicalcenteramultistakeholderperspective
AT doshii implementationofacostandvariationreductionprogramforhemostasisproductsatalargeacademicmedicalcenteramultistakeholderperspective
AT oharam implementationofacostandvariationreductionprogramforhemostasisproductsatalargeacademicmedicalcenteramultistakeholderperspective
AT silbera implementationofacostandvariationreductionprogramforhemostasisproductsatalargeacademicmedicalcenteramultistakeholderperspective
AT vasileffwk implementationofacostandvariationreductionprogramforhemostasisproductsatalargeacademicmedicalcenteramultistakeholderperspective